On Monday, September 5, another meeting of the Transparency Council.
AOTMiT: The Transparency Council will evaluate, among others, the drug for acute promyelocytic leukemia
Published Aug. 26, 2022 08:24
Źródło: AOTMiT
The agenda includes:
Preparation of a position on the legitimacy of granting consent for the reimbursement of the Tript-OH (oxitriptan) medicinal product in the indication: tetrahydrobiopterin deficits.
Preparation of opinions on draft health policy programs of local government units:
• "Treatment of infertility by in vitro fertilization for the inhabitants of Jelenia Góra in the years 2022-2026",
• "Program of health policy in the field of diagnosis and treatment of infertility for the inhabitants of the Olkusz Poviat",
• "A health policy program for the prevention of meningococcal infections for children from the Kielce Commune.
Preparation of an opinion on the reimbursement of drugs containing the active substance arsenicum trioxidum in the indication: C92.4 acute promyelocytic leukemia in: patients under 18 years of age diagnosed with acute promyelocytic leukemia characterized by the t (15; 17) translocation and/or the presence of the PML gene/RAR-alpha.
Source: AOTMiT
